No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development
Transcenta Debuts Promising Anti-Tumor Activity of Novel LIV-1 Targeting ADCs With Site-Specific Conjugated Topo I Inhibitor Payload in TNBC Tumor Models at 2024 SABCS
ADC Therapeutics Price Target Maintained With a $10.00/Share by Guggenheim
ADC Therapeutics Analyst Ratings
ADC Therapeutics Shares Drop After Trial Results
H.C. Wainwright Maintains ADC Therapeutics(ADCT.US) With Buy Rating, Maintains Target Price $8
Unlock the Full List